Over the coming years, the market for stentless bioprostheses is anticipated to increase significantly, mostly due to the rising need for minimally invasive cardiac valves and related technologies. A multitude of variables, including an ageing population, an increase in cardiovascular disease incidence, and technological developments in medical equipment, are fueling this need. Additionally, because of their greater longevity and improved hemodynamic results, stentless bioprostheses are predicted to gain popularity over conventional heart valves, which will be advantageous for the industry.
The latest report, titled ‘Global Stentless Bioprostheses Market,’ comprises a profound analysis of the fundamental parameters contributing to the global Stentless Bioprostheses market scenario. The research report provides the reader with an in-depth interpretation of the Stentless Bioprostheses market dynamics, including the crucial drivers, opportunities, threats, and challenges. The report also describes the key business strategies, demand and supply ratios, leading regions, and the renowned market players, in a nutshell, offering a futuristic outlook of the overall Stentless Bioprostheses industry.
Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/1439
The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Stentless Bioprostheses market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic.
The leading market contenders listed in the report are:
LeMaitre Vascular, Inc., Medtronic, CryoLife, Inc., Braile Biomédica, Colibri Heart Valve, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Pulmonx Corporation, Abbott
Some Key Highlights From the Report
- Stentless Bioprostheses is a type of cardiac tissue valve which does not contain stents. It is an artificial device made up of biological material like porcine or bovine pericardial tissue, and is used in aortic valve replacement procedures. This technology has been around for more than two decades now and provides several advantages over its stented counterpart, such as better hemodynamic performance, improved patient comfort and recovery time, as well as decreased risk of post-operative complications.
- The major market players operating in the global stentless bioprostheses market include LeMaitre Vascular, Inc., Medtronic, CryoLife, Inc., Braile Biomédica, Colibri Heart Valve, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Pulmonx Corporation, Abbott, and others.
- The companies are focusing on product launches, acquisitions and collaborations to gain competitive advantage in the market. For instance, in February 2019, Medtronic acquired Mazor Robotics Ltd., a medical device company operating in the spinal surgery industry. This acquisition is anticipated to enhance Medtronic’s presence in the global stentless bioprostheses market.
- Furthermore, increasing number of strategic partnerships and collaborations among companies is anticipated to drive the global stentless bioprostheses market during the forecast period. For instance, in April 2019, LivaNova PLC entered into a strategic partnership with Epicore to expand its product portfolio of cardiac valve therapies. This partnership is expected to enable LivaNova to gain significant share in the global stentless bioprostheses market.
- The xenograft segment revenue is expected to account for largest revenue share during the forecast period due to their superior hemodynamic performance in comparison to mechanical valves and other stentless bioprostheses. However, homograft segment is expected to witness significant growth over the forecast period owing to various factors such as cost-effectiveness, availability of allografts, reduced risk of valve calcification, and improved patient outcomes.
- The aortic valve replacement segment is expected to account for largest revenue share in the global stentless bioprostheses market during the forecast period due to increasing prevalence of aortic valve disease and technological advancements. Increasing number of clinical trials for the development of effective stentless bioprostheses further fuels market growth.
- The hospitals segment is expected to account for largest revenue share in the global stentless bioprostheses market during the forecast period due to availability of advanced medical facilities and increasing number of surgeries in these settings. The ambulatory surgical centers segment is projected to register significant growth during the forecast period due to growing preference for minimally invasive surgical procedures, which are cost-effective.
- North America stentless bioprostheses market is expected to account for largest revenue share during the forecast period due to increasing incidences of heart valve diseases and presence of well-established healthcare infrastructure in the region.
Emergen Research has segmented the global Stentless Bioprostheses market on the basis of type, application, end-use, and region:
Segments Covered in this report are:
Type Outlook (Revenue, USD Million; 2019–2030)
- Porcine tissue
- Bovine tissue
- Allograft (Homograft)
Application Outlook (Revenue, USD Million; 2019–2030)
- Aortic valve replacement
- Bicuspid valve replacement
- Tricuspid valve replacement
- Pulmonary valve replacement
- Endobronchial valve replacement
End-Use Outlook (Revenue, USD Million; 2019–2030)
- Ambulatory surgical centers
The various regions analyzed in the report include:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Objectives of the Report:
- Analysis and estimation of the Stentless Bioprostheses Market size and share for the projected period of 2022-2030
- Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape
- Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Stentless Bioprostheses Market
- Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments
- Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.